Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) Equity Average (2023 - 2025)

Zenas BioPharma has reported Equity Average over the past 3 years, most recently at $219.3 million for Q4 2025.

  • Quarterly results put Equity Average at $219.3 million for Q4 2025, down 34.73% from a year ago — trailing twelve months through Dec 2025 was $219.3 million (down 34.73% YoY), and the annual figure for FY2025 was $277.3 million, up 539.41%.
  • Equity Average for Q4 2025 was $219.3 million at Zenas BioPharma, up from $218.0 million in the prior quarter.
  • Over the last five years, Equity Average for ZBIO hit a ceiling of $335.9 million in Q4 2024 and a floor of -$270.6 million in Q2 2024.
  • Median Equity Average over the past 3 years was $218.0 million (2025), compared with a mean of $71.7 million.
  • Peak annual rise in Equity Average hit 517.18% in 2025, while the deepest fall reached 34.73% in 2025.
  • Zenas BioPharma's Equity Average stood at -$214.0 million in 2023, then surged by 257.0% to $335.9 million in 2024, then plummeted by 34.73% to $219.3 million in 2025.
  • The last three reported values for Equity Average were $219.3 million (Q4 2025), $218.0 million (Q3 2025), and $262.0 million (Q2 2025) per Business Quant data.